INTERRUPTION OF HEPATIC INFLOW is a common procedure during trauma surgery, liver transplantation, and resectional surgery. However, the resulting period of hepatic ischemia and subsequent reperfusion can lead to liver injury and dysfunction through the initiation of a biphasic inflammatory response. The acute phase of this response is characterized by activation of Kupffer cells and their subsequent production and release of reactive oxygen species leading to an oxidative shift in the hepatic redox state (13) (14) (15) . This causes mild injury to the hepatic parenchyma, but the oxidative state is thought to activate redox-sensitive transcription factors, such as NF-B and activator protein (AP-1), that control the expression of proinflammatory mediators, such as IL-12 and TNF-␣ (5, 18, 22, 27, 31) . The production of these mediators leads to a second phase of liver injury by inducing the expression of secondary mediators, including neutrophil-attracting CXC chemokines and endothelial cell adhesion molecules that mediate the adhesion and transmigration of neutrophils from the vascular space into the hepatic parenchyma (3, 4, 21) . Accumulated neutrophils release oxidants and proteases that directly injure hepatocytes and vascular endothelial cells and may also obstruct hepatic sinusoids resulting in hepatic hypoperfusion (17) .
Injury to hepatocytes leading to liver dysfunction is the endpoint of this response, yet most of the attempts to limit this injury have targeted proinflammatory mediators. Much less attention has been directed toward the endogenous mechanisms by which hepatocytes try to protect themselves from injury during this response. Hepatocellular injury during both the initial and later phases of ischemia-reperfusion injury is caused in large part by reactive oxygen species (13) (14) (15) . Peroxisomes, which are subcellular organelles within the hepatocyte, contain a battery of antioxidant enzymes and may help protect hepatocytes from oxidative damage. Proliferation of peroxisomes in hepatocytes is induced, at least in part, by activation of the transcription factor peroxisome proliferator-activated receptor-␣ (PPAR␣) (2, 6) . PPAR␣ is a member of the nuclear receptor superfamily and within the liver is known to be expressed in hepatocytes but not Kupffer cells (1, 28) . Activation of PPAR␣ by synthetic ligands, such as clofibrate, induces peroxisome proliferation, and, in rodents, long-term treatment leads to hepatocarcinogenesis (28) .
In the present studies, we employed PPAR␣-deficient (PPAR␣ Ϫ/Ϫ ) mice to examine the role of this transcription factor in the regulation of hepatic ischemia-reperfusion injury. Here we show that PPAR␣ Ϫ/Ϫ mice have significantly more postischemic injury than wild-type mice. There were no differences in proinflammatory mediator production between PPAR␣ Ϫ/Ϫ and wild-type mice. However, we found that livers from PPAR␣ Ϫ/Ϫ mice expressed less inducible nitric oxide (NO) synthase (iNOS) than wild-type mice. In addition, treatment of cultured murine hepatocytes with WY-14643, a specific agonist of PPAR␣, protected cells against oxidant-induced injury. These findings suggest that PPAR␣ is an important regulator of postischemic liver injury and implicate a hepatocyte-specific therapeutic target for the treatment of inflammatory liver injury.
MATERIALS AND METHODS

Model of hepatic ischemia-reperfusion injury.
Wild-type and PPAR␣ Ϫ/Ϫ mice on a 129 background and C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME). Male mice 8-10 wk of age were used in all experiments. This project was approved by the University of Cincinnati Animal Care and Use Committee and conforms to the National Institutes of Health guidelines. Partial hepatic ischemia was induced as described previously (21) . Briefly, mice were anaesthetized with pentobarbital sodium (60 mg/kg ip). A midline laparotomy was performed, and an atraumatic clip was used to interrupt blood supply to the left lateral and median lobes of the liver. After 90 min of partial hepatic ischemia, the clip was removed to initiate hepatic reperfusion. Sham control mice underwent the same protocol without vascular occlusion. For experiments using the PPAR␣ agonist WY-14643 (Biomol, Plymouth Meeting, PA), C57BL/6 mice were injected intravenously with 10 mg/kg WY-14643 or vehicle 1 h before ischemia. Mice were killed after the indicated periods of reperfusion, and blood and liver samples were taken for analysis.
Western blot. Frozen liver samples were homogenized in lysis buffer (10 mM HEPES, pH 7.9, 150 mM NaCl, 1 mM EDTA, 0.6% Nonident P-40, 0.5 mM PMSF, 1 g/ml leupeptin, 1 g/ml aprotonin, 10 g/ml soybean trypsin inhibitor, 1 g/ml pepstatin) on ice. Homogenates were sonicated and centrifuged at 5,000 rpm to remove cellular debris. Protein concentration was determined by bicinchoninic acid assay with trichloroacetic acid precipitation using BSA as a reference standard (Pierce). Liver protein (100 g) was electrophoresed in a denaturing 10% polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. Nonspecific binding sites were blocked with TBS (40 mM Tris, pH 7.6, 300 mM NaCl) containing 5% nonfat dry milk for 1 h at room temperature. Membranes were then incubated in a 1:500 dilution of rabbit polyclonal anti-mouse peroxisome membrane protein-70 (PMP70; Affinity Bioreagents, Golden, CO) or 1:250 dilution of rabbit polyclonal anti-mouse iNOS (Santa Cruz Biotechnology, Santa Cruz, CA) in TBS with 0.1% Tween 20 (TBST). After three washes in TBST, membranes were incubated in a 1:5,000 dilution of horseradish peroxidase-conjugated donkey anti-rabbit IgG (Santa Cruz Biotechnology). Immunoreactive proteins were detected by enhanced chemiluminescence.
Blood and tissue analysis. Blood was obtained by cardiac puncture at the time of death for analysis of serum alanine aminotransferase (ALT) as an index of hepatocellular injury. Measurements of serum ALT were made by using a diagnostic kit (Sigma, St. Louis, MO). Serum samples were also analyzed for TNF-␣ and macrophage inflammatory protein-2 (MIP-2) by sandwich ELISA according to manufacturer's instructions (R&D Systems, Minneapolis, MN). Analysis of nitrite/nitrate in liver lysates and serum were performed by using a diagnostic kit from Oxis International (Portland, OR) according to manufacturer's instructions.
MPO assay. Liver MPO content was assessed by methods similar to those of Schierwagen et al. (29) . Liver tissue (100 mg) was homogenized in 2 ml of buffer A (3.4 mM KH 2PO4, 16 mM Na2HPO4, pH 7.4). After centrifugation for 20 min at 10,000 g, the pellet was resuspended in 10 volumes of buffer B (43.2 mM KH2PO4, 6.5 mM Na2PO4, 10 mM EDTA, 0.5% hexadecyltrimethylammonium, pH 6.0) and sonicated for 10 s. After being heated for 2 h at 60°C, the supernatant was reacted with 3,3Ј,5,5Ј-tetramethylbenzidine (Sigma), and optical density was determined at 655 nm.
EMSA. Nuclear extracts of liver tissue were prepared by the method of Deryckere and Gannon (10) and analyzed by EMSA. Briefly, double-stranded NF-B or AP-1 consensus oligonucleotides (Promega, Madison, WI) were end labeled with ␥[
32 P]ATP (3,000 Ci/ mmol at 10 mCi/ml; Amersham, Arlington Heights, IL). Binding reactions containing equal amounts of nuclear protein extract (20 g) and 35 fmol (ϳ50,000 counts/min, Cherenkov counting) of oligonucleotide were incubated at room temperature for 30 min. Reaction volumes were held constant to 15 l. Reaction products were separated in a native 4% polyacrylamide gel and analyzed by autoradiography.
Hepatocyte culture and cytotoxicity assay. Mouse hepatocytes (AML-12; American Type Culture Collection, Manassas, VA) were cultured in a 1:1 mixture of DMEM and Ham's F-12 media, supplemented with 10% fetal bovine serum, 1% insulin-transferrin-selenium G, 1% penicillin-streptomycin, and 40 ng/ml dexamethasone. Then 1 ϫ 10 5 cells/well were seeded in 96-well microplates. Twenty-four hours later, cells were treated with either media or WY-14643 in media (5-100 M; BioMol, Plymouth Meeting, PA). One hour later, cells were stimulated with 1 mM H 2O2 (final concentration). Twelve hours later, cytotoxicity was analyzed by using the CytoTox-ONE homogeneous membrane integrity assay (Promega) according to the manufacturer's instructions. This assay was a sensitive, modified lactate dehydrogenase assay.
Statistical analysis. All data are expressed as means Ϯ SE. Data were analyzed with a one-way ANOVA with subsequent StudentNewman-Keuls test. Differences were considered significant when P Ͻ 0.05.
RESULTS
Peroxisome proliferation occurs after ischemia-reperfusion.
Because PPAR␣ activation is linked to the proliferation of peroxisomes, we sought to determine whether peroxisome proliferation was induced by hepatic ischemia-reperfusion and whether this process was dependent on PPAR␣. Western blot analysis of the PMP70 was performed on liver protein extracts from sham-operated mice and mice undergoing ischemia and 8 h of reperfusion. Figure 1 shows that abundant PMP70 protein was present in sham-operated wild-type mice but that sham-operated PPAR␣ Ϫ/Ϫ mice had far less expression. After ischemia-reperfusion, there was a significant increase in PMP70 expression in wild-type mice and PPAR␣ Ϫ/Ϫ mice, but wild-type mice appeared to have more PMP70 than PPAR␣ Ϫ/Ϫ , suggesting that PPAR␣ was required for full induction of peroxisome proliferation.
PPAR␣ regulates neutrophil accumulation and hepatocellular injury. To determine whether PPAR␣ was involved in the regulation of hepatic ischemia-reperfusion injury, we assessed the response of wild-type and PPAR␣ Ϫ/Ϫ mice to ischemiareperfusion. After ischemia and 4 h of reperfusion, there were no differences between wild-type and PPAR␣ Ϫ/Ϫ mice in the extent of hepatocellular injury, as measured by serum levels of ALT (wild-type, 5,909 Ϯ 502 IU/l; PPAR␣ Ϫ/Ϫ , 5,916 Ϯ 394 IU/l). However, after ischemia and 8 h of reperfusion, hepatocellular injury was significantly increased in PPAR␣ Ϫ/Ϫ mice ( Fig. 2A) . Because much of the injury to hepatocytes at this time point is thought to be due to reactive oxygen species and proteases released from recruited neutrophils, we then examined whether PPAR␣ deficiency caused any change in the hepatic recruitment of neutrophils. After ischemia and 4 h of reperfusion, there was no difference in liver content of MPO, a surrogate marker of neutrophil accumulation (wild-type, 2.30 Ϯ 0.18 U/g; PPAR␣ Ϫ/Ϫ , 3.43 Ϯ 0.69 U/g). In contrast, after ischemia and 8 h of reperfusion, neutrophil accumulation was significantly increased in PPAR␣ Ϫ/Ϫ mice, compared with wild-type mice (Fig. 2B) .
We then conducted experiments with the specific PPAR␣ agonist WY-14643. Treatment of C57BL/6 mice with 10 mg/kg iv WY-14643 1 h before ischemia resulted in a modest but significant reduction in hepatocellular injury (Fig. 3A) . A similar reduction, yet not statistically significant, was observed when liver content of MPO was measured (Fig. 3B) . To determine whether WY-14643 reduced hepatocellular injury directly through PPAR␣ activation, we treated wild-type and PPAR␣ Ϫ/Ϫ mice with 10 mg/kg WY-14643 and assessed the extent of liver injury after ischemia and 8 h of reperfusion. In wild-type mice, WY-14643 significantly reduced hepatocellular injury (Fig. 4) . However, in PPAR␣ Ϫ/Ϫ mice, no effect of WY-14643 was observed. These studies suggest that a single treatment with WY-14643 confers protective effects against ischemia-reperfusion injury through activation of PPAR␣.
PPAR␣ does not regulate hepatic production of proinflammatory cytokines and chemokines. Recruitment of neutrophils to the liver after ischemia-reperfusion has been shown to be controlled in large part by the expression of proinflammatory cytokines such as TNF-␣ (5) and CXC chemokines such as MIP-2 (21). The gene expression of these mediators is under the control of the transcription factors NF-B and AP-1 (18, 27), and there is evidence that PPAR␣ may negatively regulate NF-B and AP-1 in some cell types (7, 8, 9) . Therefore, we sought to determine whether PPAR␣ deficiency altered the hepatic inflammatory response to ischemia-reperfusion by altering transcription factor activation and production of inflammatory mediators. No differences in NF-B or AP-1 activation were detected between sham-operated wild-type and PPAR␣ Ϫ/Ϫ mice (Fig. 5 ). Ischemia and 8 h of reperfusion resulted in a marked increase in both NF-B and AP-1 activation in wild-type mice. In livers from PPAR␣ Ϫ/Ϫ mice there was a slight but consistent increase in the activation of both NF-B and AP-1 (Fig. 5) . We then assessed whether these apparent differences corresponded with increased production of the proinflammatory mediators TNF-␣ and MIP-2. Surprisingly, no differences were detected in the serum levels of TNF-␣ and MIP-2 in wild-type and PPAR␣ Ϫ/Ϫ mice (Fig. 6 ). Consistent with these findings, wild-type mice receiving 10 mg/kg WY-14643 showed no significant changes in serum levels of TNF-␣ compared with untreated mice (Table 1) despite having significantly reduced hepatocellular injury (Fig. 3A) .
iNOS expression is decreased in PPAR␣ Ϫ/Ϫ mice. Because iNOS expression has been shown to be protective in models of hepatic ischemia-reperfusion (11) and because it has recently been shown that iNOS is associated with the membranes of peroxisomes (30), we investigated whether the expression of this potentially hepatoprotective enzyme was altered in PPAR␣ Ϫ/Ϫ mice. Western blot analysis of liver protein extracts demonstrated that there was no detectable difference in iNOS expression between sham-operated wild-type and PPAR␣ Ϫ/Ϫ mice (Fig. 7) . However, after ischemia and 8 h of reperfusion, there was a marked increase in the expression of iNOS in wild-type mice but no increase in PPAR␣ Ϫ/Ϫ mice (Fig. 7) . Additionally, in both wild-type and PPAR␣ Ϫ/Ϫ mice undergoing ischemia-reperfusion, a smaller, faster, migrating form of iNOS was detected. A similar band was also detected in a positive control obtained from activated RAW cells (Fig.  7 ) and may represent a degradation product found in activated cells.
To determine whether expression of endothelial NOS (eNOS) was altered in PPAR␣ Ϫ/Ϫ mice, we performed a Western blot analysis of liver protein extracts for eNOS. In contrast to iNOS, we found similar expression of eNOS protein in all groups. There were no differences in eNOS expression between wild-type and PPAR␣ Ϫ/Ϫ sham-operated mice, nor was there any induction of eNOS after ischemia-reperfusion in either of these mice (data not shown).
To examine whether the reduced iNOS protein expression observed in PPAR␣ Ϫ/Ϫ mice was accompanied by reduced appearance of the NO metabolites nitrite and nitrate, we examined nitrite/nitrate levels in liver lysates and serum. We found that nitrite/nitrate levels were significantly increased by ischemia-reperfusion in both wild-type and PPAR␣ Ϫ/Ϫ mice in liver lysates but not in serum (Table 2 ). There was no differ- Ϫ/Ϫ mice exhibited enhanced hepatic ischemia-reperfusion injury and because the hepatocellular injury observed after ischemia-reperfusion is largely mediated by oxidant-induced cellular stress, we then sought to determine whether activation of PPAR␣ in hepatocytes was directly protective against oxidant-induced injury. With the use of an in vitro model of H 2 O 2 -induced hepatocyte injury that we (19) have previously described, cultured murine hepatocytes (AML-12) were treated with WY-14643 1 h before exposure to 1 mM H 2 O 2 . As shown in Fig. 8 , treatment with WY-14643 dose-dependently inhibited H 2 O 2 -induced cell death. These studies demonstrate that PPAR␣ activation within hepatocytes directly protects against oxidantinduced cell injury.
DISCUSSION
The findings presented herein demonstrate that PPAR␣, a transcription factor that within the liver is expressed preferentially in hepatocytes, regulates inflammatory injury induced by ischemia-reperfusion. A unique aspect of this regulation was that it was independent of the expression of the proinflammatory cytokine TNF-␣ and the CXC chemokine MIP-2. We and others have demonstrated essential roles for these two mediators in the propagation of hepatic inflammation after ischemia and reperfusion (5, 21) . TNF-␣ drives this inflammatory response by upregulating vascular cell adhesion molecules and by inducing the expression of MIP-2 and other neutrophilattracting CXC chemokines (26) . Mice nullizygous for PPAR␣ had significantly more injury to hepatocytes than did their wild-type counterparts, despite similar production of TNF-␣ and MIP-2. These findings can be explained by the fact that PPAR␣ is not expressed in Kupffer cells, which is the primary site of production of TNF-␣ and MIP-2 in this model. We did, however, observe an increase in the DNA binding of NF-B and AP-1 in liver nuclear extracts. NF-B and AP-1 are both involved in the transcriptional regulation of genes for TNF-␣ and MIP-2 (18, 27) . Unfortunately, the use of nuclear extracts from whole liver does not provide information on specific liver cell types. In fact, these experiments are likely to be more representative of hepatocytes, because these are by far the most predominant cell type in the liver. Given that PPAR␣ is found only in hepatocytes, the increased activation of NF-B and AP-1 observed probably represents the hepatocyte milieu and therefore would not be expected to have a significant impact on overall hepatic production of TNF-␣ and MIP-2 after ischemia-reperfusion. PPAR␣ Ϫ/Ϫ mice had augmented hepatocellular injury in association with a marked increase in the amount of neutrophils recruited to the liver. Neutrophils are responsible for much of the hepatocellular injury in this model, as documented by studies (16, 25) in which neutrophil depletion strategies ameliorated liver injury. Neutrophils are recruited from the vascular space through a complex series of events that involves upregulated expression of cellular adhesion molecules on hepatic vascular endothelial cells and increased production of CXC chemokines, both of which are induced by TNF-␣ (3, 4, 21) . Whereas we did not examine the expression of adhesion molecules in this study, we found no differences in the production of TNF-␣ and MIP-2, suggesting that the enhanced liver recruitment of neutrophils observed in PPAR␣ Ϫ/Ϫ mice may involve other mechanisms and/or mediators. One alternative mechanism that we examined was the possibility that PPAR␣ may regulate the expression of iNOS and therefore alter the production of NO. iNOS has been shown to localize within the peroxisomal membranes in hepatocytes (30) , and our data demonstrate that hepatic ischemia-reperfusion induces peroxisomal proliferation, an effect that is reduced in PPAR␣ Ϫ/Ϫ mice. NO is known to regulate hepatic neutrophil I/R, ischemia-reperfusion; PPAR␣, peroxisome proliferator-activated receptor-␣ *P Ͻ 0.05, compared with sham group. accumulation after ischemia-reperfusion. Nonspecific blockade of all NOS isoforms results in large increases in the number of neutrophils sequestered in the liver after ischemia-reperfusion and results in increased liver injury (24) . It was subsequently shown that this nonspecific inhibition of NOS isoforms resulted in augmented mRNA expression of P-selectin and ICAM-1 in the liver (23) . The roles of specific NOS isoforms have been studied recently by different laboratories using gene-targeted mice. These studies have provided consistent evidence that eNOS serves a protective function, because eNOS-deficient mice had increased liver injury (11, 12, 20) . However, the role of iNOS is less clear. Conflicting data exist as to whether iNOS is protective or injurious (11, 20) . We found that iNOS expression was dramatically reduced in livers from PPAR␣ Ϫ/Ϫ mice in association with augmented liver injury. However, our analysis of nitrite/nitrate in liver lysates did not detect any differences in NO metabolites between wild-type and PPAR␣ Ϫ/Ϫ mice. Because iNOS expression and activity in Kupffer cells is much greater, it is possible that Kupffer cell-derived NO metabolites may have masked any differences attributable to hepatocyte production. The precise manner in which PPAR␣ may regulate iNOS expression needs further analysis.
Complementing our studies of PPAR␣ Ϫ/Ϫ mice were experiments that employed the PPAR␣-specific agonist WY-14643. These experiments demonstrated that a single dose of WY-14643 was sufficient to reduce liver injury induced by ischemia-reperfusion. Although significant, this reduction in liver injury was not dramatic, and WY-14643 did not significantly suppress the degree of neutrophil accumulation. Higher doses of WY-14643 were no more effective than the 10 mg/kg dose employed in these studies (data not shown). A possible explanation for these findings is that hepatic ischemia-reperfusion may induce PPAR␣ activation to a near-maximal state, such that the administration of PPAR␣ agonists like WY-14643 may have little additive effect. We also found that treatment of cultured hepatocytes with WY-14643 was directly protective against oxidant-induced injury.
In summary, the present study is the first to address the important role of PPAR␣ in the liver inflammatory response to ischemia-reperfusion. Our data suggest that PPAR␣ regulates hepatic neutrophil accumulation and hepatocellular injury. This regulation does not occur through suppression of proinflammatory mediators but is associated with reduced hepatic expression of iNOS. Furthermore, activation of PPAR␣ in cultured hepatocytes was directly protective against oxidantinduced injury. These findings are of particular interest because they demonstrate that a regulatory factor expressed in liver parenchymal cells, but not in Kupffer cells, may have significant impact on the hepatic inflammatory response.
GRANTS
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-56029 and National Heart, Lung, and Blood Institute Grant HL-72552.
